Abstract
BRAF mutations occur in about 3% of all lung adenocarcinomas and V600E missense mutation characterizes about half of BRAFmutated lung adenocarcinomas and is significantly associated with micropapillary pattern and shorter disease-free and overall survival rates. In this report, we report a challenging case of a patient with a metastatic micropapillary adenocarcinoma of the lung harbouring V600E BRAF mutation who experienced a surprising protracted clinical response to metronomic vinorelbine. The possible association between the V600E BRAF mutation pathway and the effective use of vinca alkaloid is discussed.
Original language | English |
---|---|
Pages (from-to) | 426-428 |
Number of pages | 3 |
Journal | Pathologica |
Volume | 109 |
Issue number | 4 |
Publication status | Published - Dec 1 2017 |
Keywords
- Adenocarcinoma
- BRAF
- Breast
- Lung
- Metastasis
- Micropapillary
- V600E
- Vinorelbine
ASJC Scopus subject areas
- Pathology and Forensic Medicine